CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding.
The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice.
from MassDevice http://ift.tt/2hcp4DB
Cap comentari:
Publica un comentari a l'entrada